Comparative Pharmacology
Head-to-head clinical analysis: ALYFTREK versus DEXONE 4.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ALYFTREK versus DEXONE 4.
ALYFTREK vs DEXONE 4
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ALYFTREK (vutrisiran) is a transthyretin-directed small interfering RNA that binds to the 3' untranslated region of mutant and wild-type TTR mRNA, leading to its degradation via RNA interference, thereby reducing hepatic production of TTR protein and decreasing amyloid deposition.
Dexamethasone is a long-acting glucocorticoid receptor agonist, binding to glucocorticoid response elements to modulate gene transcription, resulting in anti-inflammatory, immunosuppressive, anti-allergic, and anti-shock effects.
For patients with cystic fibrosis (CF) who are heterozygous for the F508del mutation in the CFTR gene and a minimal function mutation (F/MF genotypes): elexacaftor 200 mg/tezacaftor 100 mg/ivacaftor 125 mg orally, two tablets in the morning, and ivacaftor 150 mg orally, one tablet in the evening, approximately 12 hours apart. For patients homozygous for F508del (F/F genotypes): elexacaftor 200 mg/tezacaftor 100 mg/ivacaftor 125 mg orally, two tablets in the morning, and ivacaftor 150 mg orally, one tablet in the evening.
Oral: 0.75–9 mg/day divided every 6–12 hours; IV/IM: 0.5–9 mg/day divided every 6–12 hours.
None Documented
None Documented
Terminal elimination half-life is approximately 72 hours after single dose and extends to ~120 hours at steady state due to dose-dependent elimination; allows once-weekly dosing.
Terminal elimination half-life: 2-3 hours (oral); clinical effects persist longer due to glucocorticoid receptor-mediated genomic actions
Primarily hepatic metabolism, with ~70% excreted in feces as metabolites and ~20% in urine (mostly as metabolites). <1% excreted unchanged in urine.
Renal excretion of metabolites (<5% unchanged drug); minor biliary/fecal elimination (<1%)
Category C
Category C
Corticosteroid/Beta2-Agonist Combination
Corticosteroid